Malignant cells multiplying unusually in the breast, ultimately increasing to the rest of the body if untreated. Breast cancer happens practically entirely in women. It is one of the leading causes of cancer related death, when it is the second most common cancer in women after lung, when it constitutes 23% of all cancer cases in women, moreover it presents the first in global mortality (18.6%) of cancer According to the latest statistics, breast cancer ranks the first number (2,088,849 new cases) of recorded cases worldwide, annually. Breast cancer is a significant and common disease that has a negative effect on women health, and deaths, 626,679 cases). Seventy four females have been included in the current study, they were classified into three groups depending on their health and the type of tumor suffered by patients. The first included 25 females with malignant breast tumors, the second group included 24 women who had benign breast tumors, and the last group included 25 women who appeared to be healthy. Sandwich-ELISA technique was followed for detecting of NSE concentration in the serum. Results showed a statistical significant increase of NSE concentration in the samples of malignant breast tumors as compared to those of benign breast tumors (p = 0.032). The highest levels of NSE were recorded in the samples of advanced malignancy stage (III), moreover; right breast injury had the highest proportion of cases recorded in the current study with higher levels of NSE compared to cases recorded in the left breast. Evaluation of the sensitivity% NSE showed a respectable proportion of the susceptibility of this enzyme (76 %) to the distinction between breast cancer patients and healthy individuals. Present work showed a gradual decrease in the levels of NSE after receiving the chemotherapy sequence. For the purpose of studying the possibility of using NSE as an effective tool in the follow-up response of breast cancer patients to treatment and evaluation of the healing stages on the one hand, on the other hand investigate the possibility of proliferation of cancer or recurrence, for that concentrations of NSE after receiving the last dosage of chemotherapy or (chemotherapy and radiotherapy) "according to the program suggested by the specialist" were compared with their levels in the group of patients with benign tumors and also with the control groups. Fifteen of the total patients (25 cases) who received chemotherapy (60% of all infected samples) showed significantly lower rates at the first diagnosis of the disease and this result enhances the possibility of using NSE as a tool to assess the extent of recovery of breast cancer patients.
Cite this article:
Rasha Hasan Jasim, Sara Abdalkareem Moshref. Neuron Specific Enolase: A New Marker for Diagnosis and Evaluating the Benefit of Specific Therapies in Treatment of Breast Cancer. Research J. Pharm. and Tech. 2020; 13(11):5365-5369. doi: 10.5958/0974-360X.2020.00938.5